IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances

Rhea-AI Summary

InVitro International (OTCQB: IVRO) reported strong financial results for Q1 FY '25. The company achieved sales of $244,143, marking a 15.4% increase compared to Q1 FY '24 sales of $211,625. Net income showed significant growth, reaching $33,855, representing a 91.6% increase from the previous year's Q1 figure of $17,667.

CEO W. Richard Ulmer expressed satisfaction with the quarter's progress, highlighting the company's recently announced M&A activity in Europe. Following challenges from Covid and inflation, the company maintains a vision of continued global growth in non-animal test technologies.

Positive

• Sales increased 15.4% year-over-year to $244,143
• Net income grew 91.6% to $33,855
• New M&A activity in Europe expanding market presence

Negative

• None.

Placentia, California--(Newsfile Corp. - February 4, 2025) - InVitro International (OTCQB: IVRO) today announced a solid 15.4% sales advance in Q1 of FY '25, totaling $244,143; this compares favorably to Q1 FY '24 sales of $211,625. FY '25 Q1 net income of $33,855 leapt 91.6% over the FY '24 Q1 figure of $17,667.

InVitro International's CEO and acting President, W. Richard Ulmer said: "Together with our newly announced M & A activity in Europe, our team is pleased with FY '25 first Quarter progress. Following Covid and inflationary years' challenges, InVitro International's vision of the future is continued global growth for our own, as well as all, NON-Animal test technologies."

About InVitro International, Inc.

InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services

This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.

Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239499

FAQ

What was IVRO's Q1 FY '25 revenue growth compared to Q1 FY '24?

IVRO reported Q1 FY '25 sales of $244,143, representing a 15.4% increase compared to Q1 FY '24 sales of $211,625.

How much did IVRO's net income grow in Q1 FY '25?

IVRO's net income grew by 91.6% to $33,855 in Q1 FY '25, compared to $17,667 in Q1 FY '24.

What strategic expansion has IVRO announced in Europe?

IVRO has announced new M&A (Mergers & Acquisitions) activity in Europe, although specific details were not provided in the announcement.

How is IVRO performing after COVID and inflationary challenges?

IVRO is showing strong recovery with significant sales and net income growth, demonstrating resilience after facing COVID and inflationary challenges.